The ALDH1A1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the CAL-27 human tongue squamous cell carcinoma cell line. This product constitutes a heterogeneous pool of cells harboring targeted disruptions in the ALDH1A1 gene, generated via non-homologous end joining repair following Cas9-mediated DNA cleavage. The polyclonal format provides a robust loss-of-function model without the biases of single-cell cloning, enabling population-level studies of ALDH1A1 depletion. Knockout of ALDH1A1 impairs its enzymatic activities, including retinaldehyde oxidation to retinoic acid and aldehyde detoxification, making these cells ideal for dissecting ALDH1A1-dependent signaling and functional phenotypes.
The parental CAL-27 cell line (ATCC CRL-2095) is a well-established adherent, epithelial-like model derived from a human tongue squamous cell carcinoma. It is widely utilized in head and neck squamous cell carcinoma (HNSCC) research, particularly for studies of tumor invasion, metastatic behavior, and drug response. CAL-27 cells exhibit features of epithelial-mesenchymal transition and express markers associated with cancer stemness, rendering them a relevant platform for exploring mechanisms of chemoresistance and recurrence in oral cancer. The cell line??s genetic background and phenotypic plasticity make it suitable for CRISPR-based genome editing applications to investigate gene function in HNSCC pathogenesis.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid, a critical morphogen and transcriptional regulator. Retinoic acid binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which heterodimerize and activate the transcription of target genes, including HOX clusters and RAR??, essential for cellular differentiation and development. ALDH1A1 also detoxifies reactive aldehydes, protecting cells from oxidative stress. In stem cell biology, ALDH1A1 activity is a hallmark of stemness, contributing to the maintenance of undifferentiated states and self-renewal through the regulation of pluripotency factors such as NANOG, OCT4, and SOX2. The enzyme??s expression is modulated by upstream signals including retinoic acid feedback, Notch signaling, HIF-1?? under hypoxia, the PI3K/AKT pathway, and the C/EBP?? transcription factor. ALDH1A1 cooperates with other ALDH isoforms (ALDH1A2, ALDH1A3) and cellular retinol-binding proteins (CRABP1, CRABP2) to fine-tune retinoic acid synthesis and signaling dynamics.
In the context of CAL-27 HNSCC cells, ALDH1A1 is intimately linked to the cancer stem cell phenotype and therapeutic resistance. ALDH1A1-positive populations in HNSCC are associated with enhanced tumor-initiating capacity, sphere formation, and reduced sensitivity to chemotherapy and radiotherapy. The mechanistic role of ALDH1A1 in detoxifying aldehydes derived from lipid peroxidation and chemotherapeutic agents underpins its contribution to cytoprotection. Disruption of ALDH1A1 in CAL-27 cells is therefore expected to attenuate retinoic acid-signaling output, diminish aldehyde clearance, and deplete the stem-like cell fraction, thereby reducing self-renewal, migration, and invasion. This polyclonal knockout model thus offers a powerful tool to interrogate ALDH1A1-dependent pathways that drive aggressive HNSCC behavior and poor clinical prognosis.
This ALDH1A1 knockout product is suited for a broad range of experimental applications in cancer biology and drug discovery. Researchers can utilize it to examine retinoic acid signaling dynamics via retinoic acid reporter assays and transcriptomic profiling (RNA-seq), or to assess stemness properties using the ALDEFLUOR assay, sphere formation efficiency, and flow cytometric analysis of CD44/CD133 and ALDH enzyme activity. Functional consequences of ALDH1A1 loss on migration/invasion can be evaluated in Transwell or wound-healing assays, while drug sensitivity testing under standard chemotherapeutics (e.g., cisplatin, 5-fluorouracil) can reveal mechanisms of chemoresistance. Additional downstream analyses, such as Western blotting and RT-qPCR for target genes (HOX, RAR??) and stemness markers (NANOG, OCT4, SOX2), enable detailed molecular characterization. This model also facilitates differentiation therapy studies by exploring retinoic acid-mediated reversion of malignant phenotypes. For further technical inquiries, please contact Ascent Research.
